Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Nov 18, 2015; 7(26): 2681-2687
Published online Nov 18, 2015. doi: 10.4254/wjh.v7.i26.2681
Published online Nov 18, 2015. doi: 10.4254/wjh.v7.i26.2681
Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C
Hirayuki Enomoto, Shuhei Nishiguchi, Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan
Author contributions: All authors participated in the studies; Enomoto H and Nishiguchi S wrote and edited the manuscript; Enomoto H and Nishiguchi S were involved in the manuscript revision and approved the final version of the manuscript.
Conflict-of-interest statement: None of the authors have conflicts of interest to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hirayuki Enomoto, MD, PhD, Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Mukogawa-cho 1-1, Nishinomiya, Hyogo 663-8501, Japan. enomoto@hyo-med.ac.jp
Telephone: +81-798-456472 Fax: +81-798-456474
Received: June 27, 2015
Peer-review started: June 30, 2015
First decision: August 16, 2015
Revised: October 15, 2015
Accepted: November 3, 2015
Article in press: November 4, 2015
Published online: November 18, 2015
Peer-review started: June 30, 2015
First decision: August 16, 2015
Revised: October 15, 2015
Accepted: November 3, 2015
Article in press: November 4, 2015
Published online: November 18, 2015
Core Tip
Core tip: Interferon-α (IFN-α) therapy has been playing a central role in anti-hepatitis C virus (HCV) strategies, and several viral and host factors related to the treatment efficacy have been identified. After the development of pegylated-IFN-α (Peg-IFN-α), the clinical impact of anti-IFN-α neutralizing antibodies in the treatment for HCV infection has not been sufficiently addressed. We recently found that anti-IFN-α neutralizing antibodies were associated with a non-response to Peg-IFN-α treatment. Our findings provide important information for the treatment of chronic hepatitis C in the clinical setting.